WBUR4d
From politics to the lab: The push for psychedelics in Mass.
New research, a potential state ballot measure and pending decisions from the FDA are putting psychedelics are on a path that ...
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on developing next-generation neuropsychiatric therapeutics, today announced that the U.S.
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology ...
Pharmabiz1d
US FDA approves Freedom Biosciences’ IND application for FREE001 in patients with treatment-resistant depression
US FDA approves Freedom Biosciences’ IND application for FREE001 in patients with treatment-resistant depression: San Francisco Saturday, April 27, 2024, 10:00 Hrs [IST] Freedom ...